ZFIN Fish: nr3c1^s357/s357

ZFIN ID: ZDB-FISH-150901-16813

ZFIN ID: ZDB-FISH-150901-16813

Fish name:	nr3c1^s357/s357
Genotype:	nr3c1^s357/s357
Targeting Reagent:	none

HUMAN DISEASE MODELED by nr3c1^s357/s357

Human Disease	Conditions	Citations
depressive disorder	standard conditions	Ziv et al., 2013
generalized anxiety disorder	standard conditions	Sireeni et al., 2020

GENE EXPRESSION
Gene expression in nr3c1^s357/s357

RNA expression

Expressed Gene	Structure	Conditions	Figures
drd1b	whole organism	control	Fig. 4 from Muto et al., 2013
	whole organism	chemical treatment: drug	Fig. 4 from Muto et al., 2013
drd2b	whole organism	control	Fig. 4 from Muto et al., 2013
	whole organism	chemical treatment: drug	Fig. 4 from Muto et al., 2013
gnas	whole organism	control	Fig. 4 from Muto et al., 2013
	whole organism	chemical treatment: drug	Fig. 4 from Muto et al., 2013
gnat2	whole organism	control	Fig. 4 from Muto et al., 2013
	whole organism	chemical treatment: drug	Fig. 4 from Muto et al., 2013
myb	hematopoietic multipotent progenitor cell	standard conditions	Fig. 6 from Kwan et al., 2016
nr3c1	whole organism	standard conditions	Fig. S1 from Facchinello et al., 2017
opn1mw1	whole organism	control	Fig. 4 from Muto et al., 2013
	whole organism	chemical treatment: drug	Fig. 4 from Muto et al., 2013
pomca	hypophysis whole organism	standard conditions	Fig. 4 from Muto et al., 2013 Fig. 4 from Griffiths et al., 2012
	hypophysis whole organism	chemical treatment: pharmaceutical	Fig. 4 from Muto et al., 2013 Fig. 4 from Griffiths et al., 2012
rag2	thymus T cell	standard conditions	Fig. 6 from Kwan et al., 2016
rho	retinal rod cell	standard conditions	Fig. 6 from Muto et al., 2013
	retinal rod cell	lighting conditions	Fig. 6 from Muto et al., 2013
runx1	ventral wall of dorsal aorta hematopoietic multipotent progenitor cell	control	Fig. 6 from Kwan et al., 2016
	ventral wall of dorsal aorta hematopoietic multipotent progenitor cell	chemical treatment by environment: serotonin	Fig. 6 from Kwan et al., 2016
th2	whole organism	control	Fig. 4 from Muto et al., 2013
	whole organism	chemical treatment: drug	Fig. 4 from Muto et al., 2013

Protein expression

Antibody	Structure	Conditions	Figures
Ab1-glul	Muller cell	standard conditions	Fig. 5 from Muto et al., 2013
Ab3-th	retina dopaminergic neuron	standard conditions	Fig. 5 from Muto et al., 2013
Ab2-sag	retinal cone cell retinal rod cell photoreceptor outer segment	standard conditions	Fig. 6 from Muto et al., 2013
Ab2-sag	retinal cone cell photoreceptor outer segment retinal rod cell	lighting conditions	Fig. 6 from Muto et al., 2013

Reporter gene expression No data available

PHENOTYPE
Phenotype in nr3c1^s357/s357

Phenotype	Conditions	Figures
camera-type eye photoreceptor cell differentiation process quality, normal	lighting conditions	Fig. 6 from Muto et al., 2013
camera-type eye photoreceptor cell differentiation process quality, normal	standard conditions	Fig. 6 from Muto et al., 2013
circadian behavior disrupted, abnormal	standard conditions	text only from Chiu et al., 2016
hematopoietic multipotent progenitor cell myb expression decreased amount, abnormal	standard conditions	Fig. 6 from Kwan et al., 2016
hematopoietic multipotent progenitor cell decreased amount, abnormal	standard conditions	Fig. 6 from Kwan et al., 2016
light adaption decreased process quality, abnormal	lighting conditions	Fig. 1 from Muto et al., 2013
light adaption decreased process quality, abnormal	standard conditions	Fig. 1, Fig. 2 from Muto et al., 2013
locomotory exploration behavior decreased occurrence, abnormal	standard conditions	Fig. 3 from Sireeni et al., 2020
optomotor response decreased process quality, abnormal	lighting conditions	Fig. 1 from Muto et al., 2013
optomotor response process quality, normal	standard conditions	Fig. 1 from Muto et al., 2013
phototransduction, visible light decreased process quality, abnormal	lighting conditions	Fig. 2 from Muto et al., 2013
regulation of dopamine receptor signaling pathway decreased process quality, abnormal	control	Fig. 4 from Muto et al., 2013
regulation of dopamine receptor signaling pathway decreased process quality, abnormal	chemical treatment: drug	Fig. 4 from Muto et al., 2013
retina has normal numbers of parts of type Muller cell, normal	standard conditions	Fig. 5 from Muto et al., 2013
retina has normal numbers of parts of type dopaminergic neuron, normal	standard conditions	Fig. 5 from Muto et al., 2013
sleep light phase, abnormal	standard conditions	text only from Chiu et al., 2016
startle response increased process quality, abnormal	standard conditions	Fig. 6 from Griffiths et al., 2012
swimming decreased occurrence, abnormal	standard conditions	Fig. 5 from Griffiths et al., 2012
swimming behavior decreased linear velocity, abnormal	standard conditions	Fig. 1, Fig. 2, Fig. 3 from Sireeni et al., 2020
thymus T cell rag2 expression decreased amount, abnormal	standard conditions	Fig. 6 from Kwan et al., 2016
thymus T cell decreased amount, abnormal	standard conditions	Fig. 6 from Kwan et al., 2016
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal	chemical treatment by environment: serotonin	Fig. 6 from Kwan et al., 2016
ventral wall of dorsal aorta hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal	control	Fig. 6 from Kwan et al., 2016
visual behavior decreased process quality, abnormal	standard conditions	Fig. 2 from Griffiths et al., 2012
whole organism increased pigmentation, abnormal	standard conditions	Fig. 2 from Griffiths et al., 2012
whole organism cortisol increased amount, abnormal	standard conditions	Fig. 4 from Facchinello et al., 2017
whole organism cortisol increased amount, abnormal	mechanical stress	Fig. 4 from Facchinello et al., 2017

CITATIONS (11)